Investors speak with AstraZeneca on COVID-19 vaccine
Praxis joins discussion on equitable allocation and distribution strategy
In December, Praxis joined with other investors to speak with AstraZeneca about the rollout of its COVID-19 vaccine. The investor group was keen to converse with the company about a variety of issues.
Dialogue topics included:
- Safety and effectiveness – AstraZeneca outlined steps it is taking to prioritize safety and effectiveness, and provided updates on its global trials and efforts to overcome vaccine hesitancy.
- Global access – AstraZeneca shared its strategy for equitably allocating vaccines with a limited supply, and how it approaches bilateral agreements with various countries.
- Pricing strategy post-pandemic – AstraZeneca has committed to a “no-profit” approach to its vaccine during the pandemic; discussion was on pricing strategies and affordability once health authorities declare the pandemic is over.
- Licensing and knowledge sharing – AstraZeneca is taking a more global approach than many other vaccine developers; the company shared its strategy to licensing and regional manufacturing and distribution.
It was a positive dialogue and increased understanding for both the company and investor group. Investors will continue to monitor AstraZeneca and other vaccine makers, with the goal of encouraging a vaccine that’s safe and effective, affordable, and equitably distributed around the world.
As a shareholder in AstraZeneca through the Praxis International Index Fund, Praxis engages directly with companies and encourages them to pursue business practices that support positive social change.